The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.
about
Metabolic complications of androgen deprivation therapy for prostate cancerCognitive changes associated with ADT: a review of the literaturePrevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerEfficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy.Safety of antiandrogen therapy for treating prostate cancer.Androgen deprivation therapy for prostate cancer: new concepts and concerns.Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.Estrogenic side effects of androgen deprivation therapy.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksToremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.Risk stratification in the hormonal treatment of patients with prostate cancerAndrogen-deprivation therapy and risk for biliary disease in men with prostate cancerAndrogen deprivation therapy is associated with diabetes: Evidence from meta-analysisProstate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an updateCardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerAdipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancerSkeletal complications of ADT: disease burden and treatment options.Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.Natural history and correlates of hip BMD loss with aging in men of African ancestry: the Tobago Bone Health Study.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.Correlates of trabecular and cortical volumetric BMD in men of African ancestry.Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.Progress in the mechanism and drug development of castration-resistant prostate cancer.Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancerHormonal therapies: ADT for prostate cancer: true love or heartbreak?Sexual adjustment to androgen deprivation therapy: struggles and strategies.Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy?The association of robotic surgical technology and hospital prostatectomy volumes: increasing market share through the adoption of technology.
P2860
Q24616159-8C3F5C63-18E1-464D-BD4F-4F5C90997AE0Q26822767-F26D458F-97DA-4DEB-968A-2AC35FE908ECQ33926384-838320A4-29CA-4A29-BDF8-3C9C38C51641Q33977514-E02F9739-FCD1-43B0-80B5-9C75ECAB7A00Q33977523-D5890B61-B3D4-4ACD-995B-5DAA88D4AC37Q34023510-64B7FD80-507B-4155-92E2-50D1F640D91DQ34356705-491078DB-2D4A-4A1A-9AC4-05FA5A33F6A3Q34441134-CDBF1CE7-B3F6-4B20-9E6C-57BE96292B23Q34617845-9FCFA36B-8406-4689-9345-ED2BF29A3505Q34617851-852201E1-EE21-42D9-8919-E59CB5EF9696Q34617924-5F5B00E1-CA04-4AA4-A118-48752C6CE818Q34629714-EE4AC464-2A3B-4EB6-BF3C-E6A0A3EAF65EQ34743239-A9A378A8-7AB0-4D00-9215-E46F6E3BA05EQ34960686-D2F85578-51A4-4101-AE96-7AB3E0408221Q34960850-BB2F0EFE-B796-482C-81EF-6BAE287D8C38Q35076189-10D1836A-AFA6-42C2-B59E-182792191EC0Q35951635-C0D631C9-6B94-482C-8C9A-76ED805A016BQ36018326-1C684197-8296-4279-A32D-A699944F234AQ36076214-15CC46E4-34F3-4671-AB74-8256FE8B223EQ36668905-97C7AF9F-E31A-4977-AD3B-000014DFE207Q36824256-3FEED0FE-284F-4556-B3A3-72B6B957C2FAQ36900805-6DAC1640-3391-4A68-AF33-1F01C5A59464Q37038267-34F25A03-2BA2-4941-9028-A6841F64CF0DQ37074106-E9918D06-2572-4881-B5FA-9C58BDD30F37Q37085223-4C426A4D-C3AA-49C8-AFEC-7FDBF2BB45C8Q37103095-BBB5E546-5A5D-4E83-B759-382603481AEEQ37230567-85BCDE35-1E41-4158-912D-4F79131ABCEFQ37390104-17A3E367-2069-4103-B9F9-533518F91D93Q37431937-182D9B28-E75E-4A05-94B4-28AE869619BAQ37469359-CBCF8C81-41E7-4E49-8D7E-D47684E2D60BQ37712068-8724F11B-A913-41A1-A578-5AA08BAFF2AAQ37727423-7D2D44FE-694A-4DAA-903D-E344F91D8D38Q38826609-EFCFF102-03CB-4461-8043-C9E2B8E7CC80Q41881479-76BE312C-BD2B-47E6-AD8B-A345280C302BQ42735808-EBDC2551-C57B-4905-A0BB-132C79F3E479Q45827935-E17652B8-14C6-4A1D-AA20-25ABBF48BEF8Q47674478-CBC14A95-A988-4A7D-B3E3-9D7EE958597DQ47896453-7DCB3F6A-8391-467D-B7B9-A73D2B86EB8BQ48414415-A970F73D-415B-4310-A9C8-DB793B01ECCAQ51166434-A9D90D79-434B-4F0A-A350-7574208CBE07
P2860
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The rising prevalence of andro ...... population-based cohort study.
@ast
The rising prevalence of andro ...... population-based cohort study.
@en
type
label
The rising prevalence of andro ...... population-based cohort study.
@ast
The rising prevalence of andro ...... population-based cohort study.
@en
prefLabel
The rising prevalence of andro ...... population-based cohort study.
@ast
The rising prevalence of andro ...... population-based cohort study.
@en
P2093
P2860
P1433
P1476
The rising prevalence of andro ...... population-based cohort study.
@en
P2093
David C Wennberg
Elizabeth S Walker-Corkery
F Lee Lucas
Michael A Delorenzo
Michael J Barry
P2860
P304
P356
10.1111/J.1464-410X.2006.06416.X
P577
2006-07-28T00:00:00Z